Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer

Molecular Cytogenetics

Volumn 2, Issue 1, 2009, Pages

  Yi, Yajun ^a   Nandana, Srinivas ^b   Case, Thomas ^b   Nelson, Colleen ^c   Radmilovic, Tatjana ^a   Matusik, Robert J ^b   Tsuchiya, Karen D ^d,e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CHROMOSOME 2; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENOME; MALE; MALL GENE; METASTASIS; METASTASIS SUPPRESSOR GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RASSF2 GENE; SLC27A2 GENE; SNRPB GENE; TUMOR SUPPRESSOR GENE;

MUS MUSCULUS;

EID: 80052771320     PISSN: None     EISSN: 17558166     Source Type: Journal    
DOI: 10.1186/1755-8166-2-18     Document Type: Article

References (26)

1. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. MA Rubin, AM Chinnaiyan, Lab Invest 2006 86 1099 1102 10.1038/labinvest.3700466 16983328 (Pubitemid 44423063)
2. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. S Kasper, PC Sheppard, Y Yan, N Pettigrew, AD Borowsky, GS Prins, JG Dodd, ML Duckworth, RJ Matusik, Lab Invest 1998 78 319 333 9520945 (Pubitemid 28128895)
3. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. N Masumori, TZ Thomas, P Chaurand, T Case, M Paul, S Kasper, RM Caprioli, T Tsukamoto, SB Shappell, RJ Matusik, Cancer Res 2001 61 2239 2249 11280793 (Pubitemid 32692054)
4. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. N Masumori, K Tsuchiya, WH Tu, C Lee, S Kasper, T Tsukamoto, SB Shappell, RJ Matusik, J Urol 2004 171 439 442 10.1097/01.ju.0000099826.63103.94 14665950 (Pubitemid 37549206)
5. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. DB Zimonjic, JL Pollock, P Westervelt, NC Popescu, TJ Ley, Proc Natl Acad Sci USA 2000 97 13306 13311 10.1073/pnas.97.24.13306 11087871
6. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. LW Loo, DI Grove, EM Williams, CL Neal, LA Cousens, EL Schubert, IN Holcomb, HF Massa, J Glogovac, CI Li, et al. Cancer Res 2004 64 8541 8549 10.1158/0008-5472.CAN-04-1992 15574760 (Pubitemid 39552066)
7. A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. YJ Chung, J Jonkers, H Kitson, H Fiegler, S Humphray, C Scott, S Hunt, Y Yu, I Nishijima, A Velds, et al. Genome Res 2004 14 188 196 10.1101/gr.1878804 14707179 (Pubitemid 38088540)
8. Coupled analysis of gene expression and chromosomal location. Y Yi, J Mirosevich, Y Shyr, R Matusik, AL Jr George, Genomics 2005 85 401 412 10.1016/j.ygeno.2004.11.011 15718107 (Pubitemid 40249432)
9. Strategy for encoding and comparison of gene expression signatures. Y Yi, C Li, C Miller, AL George Jr, Genome Biol 2007 8 133 10.1186/gb-2007-8-7-r133 17612401 (Pubitemid 351903204)
10. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. J Sun, W Liu, TS Adams, X Li, AR Turner, B Chang, JW Kim, SL Zheng, WB Isaacs, J Xu, Prostate 2007 67 692 700 10.1002/pros.20543 17342750 (Pubitemid 46709438)
11. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. J Lapointe, C Li, CP Giacomini, K Salari, S Huang, P Wang, M Ferrari, T Hernandez-Boussard, JD Brooks, JR Pollack, Cancer Res 2007 67 8504 8510 10.1158/0008-5472.CAN-07-0673 17875689 (Pubitemid 47437424)
12. Integrative analysis of genomic aberrations associated with prostate cancer progression. JH Kim, SM Dhanasekaran, R Mehra, SA Tomlins, W Gu, J Yu, C Kumar-Sinha, X Cao, A Dash, L Wang, et al. Cancer Res 2007 67 8229 8239 10.1158/0008-5472.CAN-07-1297 17804737 (Pubitemid 47395160)
13. Identification of tumor metastasis suppressor region on the short arm of human chromosome 20. G Goodarzi, T Mashimo, M Watabe, AP Cuthbert, RF Newbold, SK Pai, S Hirota, S Hosobe, K Miura, S Bandyopadhyay, et al. Genes Chromosomes Cancer 2001 32 33 42 10.1002/gcc.1164 11477659 (Pubitemid 32737782)
14. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. MJ Walter, JS Park, RE Ries, SK Lau, M McLellan, S Jaeger, RK Wilson, ER Mardis, TJ Ley, Proc Natl Acad Sci USA 2005 102 12513 12518 10.1073/pnas.0504247102 16113082 (Pubitemid 41266390)
15. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. JT Dong, PW Lamb, CW Rinker-Schaeffer, J Vukanovic, T Ichikawa, JT Isaacs, JC Barrett, Science 1995 268 884 886 10.1126/science. 7754374 7754374
16. Prostate cancer metastasis-suppressor genes: a current perspective. BA Yoshida, MA Chekmareva, JF Wharam, M Kadkhodaian, WM Stadler, A Boyer, K Watabe, JB Nelson, CW Rinker-Schaeffer, In Vivo 1998 12 49 58 9575426 (Pubitemid 28177279)
17. Expression of MAL, an integral protein component of the machinery for raft-mediated pical transport, in human epithelia. M Marazuela, A Acevedo, M Adrados, MA Garcia-Lopez, MA Alonso, J Histochem Cytochem 2003 51 665 674 12704214
18. DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. GE Lind, T Ahlquist, RA Lothe, Gastroenterology 2007 132 1631 1632 author reply 1632 10.1053/j.gastro.2007.03.003 17408629 (Pubitemid 46656256)
19. Loss of MAL expression in precancerous lesions of the esophagus. K Mimori, K Nishida, Y Nakamura, K Ieta, Y Yoshikawa, A Sasaki, H Ishii, MA Alonso, M Mori, Ann Surg Oncol 2007 14 1670 1677 10.1245/s10434-006-9064-2 17151798 (Pubitemid 46790982)
20. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. M Hatta, H Nagai, K Okino, M Onda, K Yoneyama, Y Ohta, H Nakayama, T Araki, M Emi, J Obstet Gynaecol Res 2004 30 53 58 10.1111/j.1341-8076.2004.00156.x 14718022 (Pubitemid 38405064)
21. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. K Mimori, T Shiraishi, K Mashino, H Sonoda, K Yamashita, K Yoshinaga, T Masuda, T Utsunomiya, MA Alonso, H Inoue, M Mori, Oncogene 2003 22 3463 3471 10.1038/sj.onc.1206378 12776198 (Pubitemid 36713744)
22. A current review of fatty acid transport proteins (SLC27). A Stahl, Pflugers Arch 2004 447 722 727 10.1007/s00424-003-1106-z 12856180 (Pubitemid 38241457)
23. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. LB Hesson, R Wilson, D Morton, C Adams, M Walker, ER Maher, F Latif, Oncogene 2005 24 3987 3994 10.1038/sj.onc.1208566 15806169 (Pubitemid 40896410)
24. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. M Endoh, G Tamura, T Honda, N Homma, M Terashima, S Nishizuka, T Motoyama, Br J Cancer 2005 93 1395 1399 10.1038/sj.bjc.6602854 16265349 (Pubitemid 41752867)
25. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. WN Cooper, RE Dickinson, A Dallol, EV Grigorieva, TV Pavlova, LB Hesson, I Bieche, M Broggini, ER Maher, ER Zabarovsky, et al. Oncogene 2008 27 1805 1811 10.1038/sj.onc.1210805 17891178 (Pubitemid 351380259)
26. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Z Zhang, D Sun, N Van do, A Tang, L Hu, G Huang, Int J Cancer 2007 120 32 38 10.1002/ijc.22185 17013896 (Pubitemid 44901914)